Drugs / Trifluridine/tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07361003 Comparator | Nov 2025 → Jan 2028 expected | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361003 ↗ |
| Known as | FTD/TPI | “Trifluridine/Tipiracil Tablets (FTD/TPI)” NCT07361003 ↗ |